| Market Cap | 11.68B | P/E | 32.37 | EPS this Y | 1.60% | Ern Qtrly Grth | -60.40% |
| Income | 357.57M | Forward P/E | 17.03 | EPS next Y | 11.10% | 50D Avg Chg | 2.00% |
| Sales | 2.97B | PEG | 2.12 | EPS past 5Y | 6.85% | 200D Avg Chg | 3.00% |
| Dividend | 1.00% | Price/Book | 2.84 | EPS next 5Y | 7.20% | 52W High Chg | -10.00% |
| Recommedations | 2.50 | Quick Ratio | 1.13 | Shares Outstanding | 47.10M | 52W Low Chg | 36.00% |
| Insider Own | 0.26% | ROA | 4.34% | Shares Float | 46.91M | Beta | 1.12 |
| Inst Own | 98.55% | ROE | 8.45% | Shares Shorted/Prior | 888.21K/1.41M | Price | 248.61 |
| Gross Margin | 55.37% | Profit Margin | 11.98% | Avg. Volume | 292,577 | Target Price | 264.50 |
| Oper. Margin | 12.70% | Earnings Date | May 2 | Volume | 424,659 | Change | -0.27% |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| JMP Securities | Market Outperform | Feb 23, 24 |
| RBC Capital | Outperform | Feb 23, 24 |
| Truist Securities | Hold | Feb 23, 24 |
| RBC Capital | Outperform | Jan 12, 24 |
| Truist Securities | Hold | Dec 22, 23 |
| Raymond James | Outperform | Dec 20, 23 |
| Morgan Stanley | Overweight | Dec 4, 23 |
| Piper Sandler | Neutral | Nov 6, 23 |
| Truist Securities | Hold | Nov 6, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Dec 27 | Sell | 250.64 | 26,256 | 6,580,804 | 18,470 | 12/29/23 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Dec 27 | Option | 104.3 | 26,256 | 2,738,501 | 44,726 | 12/29/23 |
| Klasko Stephen K. M.D. | Director Director | Dec 13 | Option | 101.12 | 3,021 | 305,484 | 7,584 | 12/15/23 |
| POWELL THOMAS E | Executive Vice Presi.. Executive Vice President & CFO | Nov 29 | Sell | 222.85 | 13,952 | 3,109,203 | 14,384 | 12/01/23 |
| POWELL THOMAS E | Executive Vice Presi.. Executive Vice President & CFO | Nov 29 | Option | 122.02 | 13,952 | 1,702,423 | 28,336 | 12/01/23 |
| Klasko Stephen K. M.D. | Director Director | Jan 27 | Option | 78.5 | 3,014 | 236,599 | 4,849 | 01/27/23 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Jan 11 | Option | 80.44 | 9,619 | 773,752 | 22,365 | 01/20/23 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Dec 30 | Sell | 250.52 | 16,343 | 4,094,248 | 15,810 | 01/04/23 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Dec 30 | Option | 78.62 | 16,343 | 1,284,887 | 32,153 | 01/04/23 |
| RANDLE STUART A | Director Director | Jun 07 | Sell | 283.31 | 3,014 | 853,896 | 4,320 | 06/09/22 |
| RANDLE STUART A | Director Director | Jun 07 | Option | 78.5 | 3,014 | 236,599 | 7,334 | 06/09/22 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Aug 20 | Sell | 376.61 | 8,987 | 3,384,594 | 25,775 | 08/20/21 |
| Kelly Liam | Chairman, President.. Chairman, President & CEO | Aug 20 | Option | 59.75 | 8,987 | 536,973 | 34,762 | 08/20/21 |
| Klasko Stephen K. M.D. | Director Director | Jul 13 | Option | 59.75 | 3,564 | 212,949 | 4,988 | 07/13/21 |
| Hicks Cameron P | Corp. VP & Chief HR.. Corp. VP & Chief HR Officer | Jun 11 | Option | 111.06 | 3,476 | 386,045 | 12,080 | 06/11/21 |
| Leyden James J | VP, General Counsel,.. VP, General Counsel, Secretary | Dec 29 | Option | 83.42 | 25,996 | 2,168,586 | 41,502 | 12/29/20 |
| Klasko Stephen K. M.D. | Director Director | Oct 28 | Option | 58.25 | 200 | 11,650 | 1,321 | 10/28/20 |
| Klasko Stephen K. M.D. | Director Director | Oct 28 | Sell | 361.38 | 200 | 72,276 | 1,121 | 10/28/20 |
| Klasko Stephen K. M.D. | Director Director | Sep 28 | Option | 58.25 | 200 | 11,650 | 1,321 | 09/28/20 |
| Klasko Stephen K. M.D. | Director Director | Sep 28 | Sell | 326.15 | 200 | 65,230 | 1,121 | 09/28/20 |